Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NanoViricides Inc NNVC

Healthcare Biotechnology
NanoViricides, Inc. is a clinical-stage company that is creating special purpose nanomaterials for antiviral therapy. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. It is focused on advancing NV-387 into Phase II human clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is its other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.


NYSEAM:NNVC - Post by User

NanoViricides Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by Danaloon Aug 29, 2012 10:48am
170 Views
Post# 20273930

let the stock price pull back.

let the stock price pull back.

should be back in the .60 soon.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities